The DepoVax™ vaccine delivery and enhancement platform represents a breakthrough in human vaccine technology. The DepoVax™ technology is an improvement on the company’s original discovery that a surprising formulation of immunogens in liposomes and then in oil carrier results in significantly enhanced immune responses. DepoVax™ is a dry product and is inherently stable. Once prepared for injection, the active components are retained in the oil phase creating a long-lasting ‘depot effect’ that elicits a potent humoral and/or cellular immunity even with a single dose.

Upon injection, the depot vaccine remains at the site of immunization for a prolonged period of time. Exposure of antigen presenting cells to the optimized mixture of antigens and immune activators that make up each DepoVax™-based vaccine allow the generation of strong cellular and humoral immune responses with a single dose. All components of the DepoVax™ platform are necessary for the optimal immune response. The DepoVax™ platform is commercially applicable, with potential for years of stability and ease of use in the clinic.

Benefits of the DepoVax™ platform include:

• Efficacious and flexible depot vaccine formulation

• Reduction in the number of doses required for efficacy from two or three to ONE and earlier onset of protection

• Multi-year antibody production and long-lasting cellular responses

• Strong and rapid immune response to a wide range of antigens

• Ability to prevent the growth of tumors in pre-clinical models with a single dose

• Ability to destroy cancer cells in pre-clinical models with a single dose (100% elimination)

• Effectiveness with low immunogenicity synthetic peptide antigens that represent the next generation of therapeutic and prophylactic vaccines

• Highly flexible format suitable for any type of antigen, including peptides, proteins and nucleic acids

• Dry storage formulation for enhanced stability of antigens

• Easy to reconstitute and administer



Immunovaccine has c